Effect of chronic hepatitis C virus infection on inflammatory lipid mediators1

Digestive and Liver Disease

Volumn 39, Issue SUPPL. 1, 2007, Pages

  Guerra, Cristina Tosti ^a   Caini, Patrizio ^a   Giannini, Carlo ^a   Giannelli, Francesca ^a   Gragnani, Laura ^a   Petrarca, Antonio ^a   Solazzo, Vera ^a   Monti, Monica ^a   Laffi, Giacomo ^a   Zignego, Anna Linda ^a  

^a Division of Rheumatology AOUC   (Italy)

Author keywords

Hepatitis C virus; Plasma PAF acetylhydrolase; Platelet activating factor

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANTIVIRUS AGENT; APOLIPOPROTEIN B100; PEGINTERFERON; PHOSPHOLIPID; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; THROMBOCYTE ACTIVATING FACTOR; VIRUS RNA;

ADULT; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; FEMALE; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; INFLAMMATION; LEUKOCYTE; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN B-100; CARRIER STATE; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MACROPHAGES; MALE; MIDDLE AGED; PLATELET ACTIVATING FACTOR; RNA, VIRAL; VASCULITIS;

EID: 34948838336     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(07)80016-8     Document Type: Article

References (50)

1. Giannini C., and Brechot C. Hepatitis C virus biology. Cell Death Differ 10 Suppl 1 (2003) S27-S38
2. Chang K. Immunopathogenesis of hepatitis C virus infection. Clin Liver Dis 7 (2003) 89-105
3. Capra F., De Maria E., Lunardi C., Marchioti L., Mezzelani P., Beri R., et al. Serum level of soluble intercellular adhesion molecule 1 in patients with chronic liver disease related to hepatitis C virus: A prognostic marker for responses to interferon treatment. J Infect Dis 181 (2000) 425-431
4. Kaplanski G., Maisonobe T., Marin V., Gres S., Robitail S., Farnarier C., et al. Vascular cell adhesion molecule-1 (VCAM-1) plays a central role in the pathogenesis of severe forms of vasculitis due to hepatitis C-associated mixed cryoglobulinemia. J Hepatol 42 (2005) 334-340
5. Cacoub P., Ghillani P., Revelen R., Thibault V., Calvez V., Charlotte F., et al. Anti-endothelial cell auto-antibodies in hepatitis C virus mixed cryoglobulinemia. J Hepatol 31 (1999) 598-603
6. Tjoelker L., and Stafforini D. Platelet-activating factor acetyl-hydrolases in health and disease. Biochim Biophys Acta 1488 (2000) 102-123
7. Prescott S. Inflammatory actions of platelet-activating factor: control by PAF acetylhydrolase. J Invest Allergol Clin Immunol 7 (1997) 416
8. Montrucchio G., Alloatti G., and Camussi G. Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev 80 (2000) 1669-1699
9. Tsoukatos D., Liapikos T., Tselepis A., Chapman M., and Ninio E. Platelet-activating factor acetylhydrolase and transacetylase activities in human plasma low-density lipoprotein. Biochem J 357 (2001) 457-464
10. Agnello V., Abel G., Elfahal M., Knight G., and Zhang Q. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 96 (1999) 12766-12771
11. Hijikata M., Shimizu Y., Kato H., Iwamoto A., Shih J., Alter H., et al. Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. J Virol 67 (1993) 1953-1958
12. Kanto T., Hayashi N., Takehara T., Hagiwara H., Mita E., Naito M., et al. Buoyant density of hepatitis C virus recovered from infected hosts: two different features in sucrose equilibrium density-gradient centtifugation related to degree of liver inflammation. Hepatology 19 (1994) 296-302
13. Manzini P., Dusheiko G., Brown J., Khakoo S., and Owen J. Hepatitis C virus (HCV) tends to associate preferentially with high-density lipoproteins by standard ultracentrifugal fractionation of plasma from patients with chronic HCV infection. Hepatol Res 11 (1998) 158-165
14. Monazahian M., Kippenberger S., Muller A., Seitz H., Bohme I., Grethe S., et al. Binding of human lipoproteins (low, very low, high density lipoproteins) to recombinant envelope proteins of hepatitis C virus. Med Microbiol Immunol Berlin 188 (2000) 177-184
15. Pumeechockchai W., Bevitt D., Agarwal K., Petropoulou T., Langer B., Belohradsky B., et al. Hepatitis C virus particles of different density in the blood of chronically infected immunocompetent and immunodeficient patients: Implications for virus clearance by antibody. J Med Virol 68 (2002) 335-342
16. Thomssen R., Bonk S., Propfe C., Heermann K., Kochel H., and Uy A. Association of hepatitis C virus in human sera with beta-lipoprotein. Med Microbiol Immunol Berlin 181 (1992) 293-300
17. Triyatni M., Saunier B., Maruvada P., Davis A., Ulianich L., Heller T., et al. Interaction of hepatitis C virus-like particles and cells: a model system for studying viral binding and entry. J Virol 76 (2002) 9335-9344
18. Pileri P., Uematsu Y., Campagnoli S., Galli G., Falugi F., Petracca R., et al. Binding of hepatitis C virus to CD81. Science 282 (1998) 938-941
19. Scarselli E., Ansuini H., Cerino R., Roccasecca R., Acali S., Filocamo G., et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 21 (2002) 5017-5025
20. Lozach P., Lortat-Jacob H., de Lacroix de Lavalette A., Staropoli I., Foung S., Amara A., et al. DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J Biol Chem 278 (2003) 20358-20366
21. Cormier E., Tsamis F., Kajumo F., Durso R., Gardner J., and Dragic T. CD81 is an entry coreceptor for hepatitis C virus. Proc Natl Acad Sci USA 101 (2004) 7270-7274
22. Germi R., Crance J., Garin D., Guimet J., Lortat-Jacob H., Ruigrok R., et al. Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption. J Med Virol 68 (2002) 206-215
23. Andre P., Komurian-Pradel F., Deforges S., Perret M., Berland J., Sodoyer M., et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 76 (2002) 6919-6928
24. Monazahian M., Bohme I., Bonk S., Koch A., Scholz C., Grethe S., et al. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol 57 (1999) 223-229
25. Maillard P., Huby T., Andreo U., Moreau M., Chapman J., and Budkowska A. The interaction of natural hepatitis C virus with human scavenger receptor SR-BI/Clal is mediated by ApoB-containing lipoproteins. FASEB J 20 (2006) 735-737
26. Zignego A., Macchia D., Monti M., Thiers V., Mazzetti M., Foschi M., et al. Infection of peripheral mononuclear blood cells by hepatitis C virus [see comments]. J Hepatol 15 (1992) 382-386
27. Zignego A., De Carli M., Monti M., Careccia G., La Villa G., Giannini C., et al. Hepatitis C virus infection of mononuclear cells from peripheral blood and liver infiltrates in chronically infected patients. J Med Virol 47 (1995) 58-64
28. Wu X., Zimmerman G., Prescott S., and Stafforini D. The p38 MAPK pathway mediates transcriptional activation of the plasma platelet-activating factor acetylhydrolase gene in macrophages stimulated with lipopolysaccharide. J Biol Chem 279 (2004) 36158-36165
29. Zignego A., Ferri C., Giannelli F., Giannini C., Caini P., Monti M., et al. Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Ann Intern Med 137 (2002) 571-580
30. Karasawa K., Harada A., Satoh N., Inoue K., and Setaka M. Plasma platelet activating factor-acetylhydrolase (PAF-AH). Prog Lipid Res 42 (2003) 93-114
31. Zignego A., and Brechot C. Extrahepatic manifestations of HCV infection: facts and controversies. J Hepatol 31 (1999) 369-376
32. Bartosch B., and Cosset F. Cell entry of hepatitis C virus. Virology 348 (2006) 1-12
33. Prescott S., McIntyre T., Zimmerman G., and Stafforini D. Sol Sherry lecture in thrombosis: molecular events in acute inflammation. Arterioscler Thromb Vasc Biol 22 (2002) 727-733
34. Zimmerman G., McIntyre T., Prescott S., and Stafforini D. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med 30 (2002) S294-S301
35. Zimmerman G., McIntyre T., Mehra M., and Prescott S. Endothelial cell-associated platelet-activating factor: a novel mechanism for signaling intercellular adhesion. J Cell Biol 110 (1990) 529-540
36. Packard C., O'Reilly D., Caslake M., McMahon A., Ford I., Cooney J., et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 343 (2000) 1148-1155
37. Quarck R., De Geest B., Stengel D., Mertens A., Lox M., Theilmeier G., et al. Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation 103 (2001) 2495-2500
38. Hara M., Matsushima T., Satoh H., Iso-o N., Noto H., Togo M., et al. Isoform-dependent cholesterol efflux from macrophages by apolipoprotein E is modulated by cell surface proteoglycans. Arterioscler Thromb Vasc Biol 23 (2003) 269-274
39. Prince A., Huima-Byron T., Parker T., and Levine D. Visualization of hepatitis C virions and putative defective interfering particles isolated from low-density lipoproteins. J Viral Hepat 3 (1996) 11-17
40. Prescott S. Platelet-activating factor: a phospholipid mediator of inflammation. In: Gallin J., and Snyderman R. (Eds). Inflammation: Basic Principles and Clinical Correlates (1999), Lippincott Williams Wilkins, Philadelphia, PA 387-396
41. Imaizumi T., Stafforini D., Yamada Y., McIntyre T., Prescott S., and Zimmerman G. Platelet-activating factor: a mediator for clinicians. J Intern Med 238 (1995) 5-20
42. Stafforini D. PAF acetylhydrolase gene polymorphisms and asthma severity. Pharmacogenomics 2 (2001) 163-175
43. Cacoub P., Maisonobe T., Thibault V., Gatel A., Servan J., Musset L., et al. Systemic vasculitis in patients with hepatitis C. J Rheumatol 28 (2001) 109-118
44. Zignego A., Ferri C., Giannini C., Monti M., La Civita L., Careccia G., et al. Hepatitis C virus genotype analysis in patients with type II mixed cryoglobulinemia. Ann Intern Med 124 (1996) 31-34
45. Agnello V., and Abel G. Localization of hepatitis C virus in cutaneous vasculitic lesions in patients with type II cryoglobulinemia. Arthritis Rheum 40 (1997) 2007-2015
46. Tjoelker L., Wilder C., Eberhardt C., Stafforini D., Dietsch G., Schimpf B., et al. Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature 374 (1995) 549-553
47. Theilmeier G., De Geest B., Van Veldhoven P., Stengel D., Michiels C., Lox M., et al. HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/-mice. FASEB J 14 (2000) 2032-2039
48. Morgan E., Boyle Jr. E., Yun W., Kovacich J., Canty Jr. T., Chi E., et al. Platelet-activating factor acetylhydrolase prevents myocardial ischemia reperfusion injury. Circulation 100 (1999) II365-II368
49. Noto H., Hara M., Karasawa K., Iso-o N., Satoh H., Togo M., et al. Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress. Arterioscler Thromb Vasc Biol 23 (2003) 829-835
50. Hase M., Tanaka M., Yokota M., and Yamada Y. Reduction in the extent of atherosclerosis in apolipoprotein E-deficient mice induced by electroporation-mediated transfer of the human plasma platelet-activating factor acetylhydrolase gene into skeletal muscle. Prostaglandins Other Lipid Mediat 70 (2002) 107-118